Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

74.53 +0.08 (+0.11%)
Official Closing Price Updated: 7:00 PM EST, Feb 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,112,733
Open 74.45
Bid (Size) 74.57 (2)
Ask (Size) 75.59 (1)
Prev. Close 74.45
Today's Range 74.23 - 75.18
52wk Range 65.00 - 81.44
Shares Outstanding 2,222,113,553
Dividend Yield 2.63%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
NeurAxis IPO Sets Stage To Take On Irritable Bowel Syndrome With A Non-Surgical Solution
As NeurAxis gears up for its upcoming IPO, we take a deep dive into the company to see if it's worth adding to your investment portfolio. 
Via Talk Markets
Big Pharma Bristol-Myers Returns $475M IL-12 Oncology Asset To Dragonfly
 
Via Benzinga

Performance

YTD
+3.14%
+3.14%
1 Month
+4.96%
+4.96%
3 Month
-5.88%
-5.88%
6 Month
+0.99%
+0.99%
1 Year
+12.60%
+12.60%

More News

Read More
Could This Indication Provide a Lift for Bristol Myers Squibb's Stock?
Via The Motley Fool
1 Company Bucks the Office REIT Trend With Higher Rents and Earnings
Via The Motley Fool
Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review
Via Investor's Business Daily
What 5 Analyst Ratings Have To Say About Bristol-Myers Squibb
Via Benzinga
Bristol Myers Jumps On Fourth-Quarter Beat Strong Earnings Outlook
Via Investor's Business Daily
Bristol Myers Squibb to Participate in the Guggenheim Healthcare Talks 2023 Oncology Conference
From Bristol Myers Squibb
Via Business Wire
Bristol-Myers Squibb (BMY) Q4 2022 Earnings Call Transcript
Via The Motley Fool
Bristol Myers Squibb Q4 Earnings And Revenues Surpass Estimates
Via Talk Markets
Revlimid Generic Competition Hurts Bristol Myers' Q4 Earnings, Issues Annual Outlook Within Expected Range
Via Benzinga
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
From Bristol Myers Squibb
Via Business Wire
A Preview Of Bristol-Myers Squibb's Earnings
Via Benzinga
Prothena Touts Encouraging Data From Early-Stage Alzheimer's Candidate
Via Benzinga
Nasdaq Futures Fly As Meta Keeps Tech Earnings' Buoyancy Intact: Will Apple, Amazon, Alphabet Toe In Line?
Via Benzinga
Bristol-Myers Squibb Unusual Options Activity For February 01
Via Benzinga
Down 14.5%, Is Pfizer Stock a Screaming Buy?
Via The Motley Fool
2 Top Dividend Stocks to Buy in 2023 and Hold Forever
Via The Motley Fool
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
Via Benzinga
Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Adult Patients with Anemia-Associated, Non-Transfusion-Dependent (NTD) Beta Thalassemia
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Announces Positive CHMP Opinion for Once-Daily Sotyktu (deucravacitinib) as a Treatment for Adults With Moderate-to-Severe Plaque Psoriasis
From Bristol Myers Squibb
Via Business Wire
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
Via The Motley Fool
Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi® (lisocabtagene maraleucel) Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
From Bristol Myers Squibb
Via Business Wire
3 Buffett-Type Stocks to Buy Right Now
Via The Motley Fool
Five Best And Worst Performing Healthcare Stocks In December 2022
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.